1. Home
  2. MESO vs ASTH Comparison

MESO vs ASTH Comparison

Compare MESO & ASTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • ASTH
  • Stock Information
  • Founded
  • MESO 2004
  • ASTH 1994
  • Country
  • MESO Australia
  • ASTH United States
  • Employees
  • MESO N/A
  • ASTH N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • ASTH Professional Services
  • Sector
  • MESO Health Care
  • ASTH Consumer Discretionary
  • Exchange
  • MESO Nasdaq
  • ASTH Nasdaq
  • Market Cap
  • MESO 1.7B
  • ASTH 1.7B
  • IPO Year
  • MESO N/A
  • ASTH N/A
  • Fundamental
  • Price
  • MESO $10.72
  • ASTH $31.38
  • Analyst Decision
  • MESO Buy
  • ASTH Strong Buy
  • Analyst Count
  • MESO 4
  • ASTH 8
  • Target Price
  • MESO $18.00
  • ASTH $53.29
  • AVG Volume (30 Days)
  • MESO 240.4K
  • ASTH 322.1K
  • Earning Date
  • MESO 02-26-2025
  • ASTH 05-08-2025
  • Dividend Yield
  • MESO N/A
  • ASTH N/A
  • EPS Growth
  • MESO N/A
  • ASTH N/A
  • EPS
  • MESO N/A
  • ASTH 0.90
  • Revenue
  • MESO $5,670,000.00
  • ASTH $2,034,540,000.00
  • Revenue This Year
  • MESO $228.57
  • ASTH $36.05
  • Revenue Next Year
  • MESO $356.77
  • ASTH $21.97
  • P/E Ratio
  • MESO N/A
  • ASTH $34.87
  • Revenue Growth
  • MESO N/A
  • ASTH 46.72
  • 52 Week Low
  • MESO $4.60
  • ASTH $23.12
  • 52 Week High
  • MESO $22.00
  • ASTH $63.20
  • Technical
  • Relative Strength Index (RSI)
  • MESO 38.38
  • ASTH 48.59
  • Support Level
  • MESO $10.26
  • ASTH $30.20
  • Resistance Level
  • MESO $11.33
  • ASTH $34.15
  • Average True Range (ATR)
  • MESO 0.75
  • ASTH 2.04
  • MACD
  • MESO 0.06
  • ASTH 0.28
  • Stochastic Oscillator
  • MESO 37.37
  • ASTH 57.45

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About ASTH Astrana Health Inc. Common Stock

Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. Its operating segment is the healthcare delivery segment.

Share on Social Networks: